Looking Beyond The Deal In England
Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?
You may also be interested in...
NHS England has struck a “first of its kind” agreement with Gilead, AbbVie and MSD to try to eliminate hepatitis C under which the companies will seek out patients who do not yet know they have the virus.
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.